The Cost of Inaction: UK Loses Billions in Pharma Investment

The cost of government inaction on reforming the UK’s pharmaceutical market is now being measured in the billions, as a standoff over pricing and spending leads to the cancellation and postponement of major investment projects. The UK economy is paying a heavy price for the failure to create a competitive environment for life sciences.
The most significant single loss is the £1bn research center that MSD has now abandoned in London. However, the true cost is far greater. It includes the unspecified, but substantial, investments that Eli Lilly has put on hold and the potential expansion that Sanofi has shelved.
This financial damage is a direct consequence of a policy framework that the industry deems unsustainable. The low spending on new medicines, the outdated NICE thresholds, and the high “clawback” rate on revenues have combined to create a market that no longer offers a viable return on large-scale, long-term investment.
Experts are warning that these losses could be just the beginning. Sir John Bell has cautioned that other CEOs are poised to pull their investments as well. The government is now facing the stark reality that the economic cost of maintaining its current policies may be far greater than the cost of reform.